| Message: | The androgen receptor (AR) plays a key role in the function of multiple organs including primary and accessory sex organs, skeletal muscle, and bone, making it an ideal therapeutic target.
Selective androgen receptor modulators (SARMs) bind to AR and exhibit bone and muscle anabolic activity. At the same time, unlike testosterone and other anabolic steroids, these non-steroidal drugs have little effect on the growth of the prostate and other secondary sex organs, giving SARMs a huge room for medical development.
The development space of SARM is becoming more and more crowded, more SARMs with different structural templates are accelerating, and various well-known pharmaceutical companies have joined the ranks of SARM development. Such as GTx/Merck, Ligand Pharmaceuticals, Kaken Pharmaceutical, BMS, Johnson & Johnson, GlaxoSmithKline (GSK), Lilly, Pfizer, Acadia pharmaceuticals, etc.
SARM has huge development potential and is becoming a new trend.
The SARM LGD3033 we call today is a new SARM developed by Ligand Pharmaceuticals.
https://www.sarmshgpharm.com/sarms-list/lgd-3033/sarm-lgd3033-reviews%ef%bc%8cbenefits%ef%bc%8cdosage%ef%bc%8ccycle-and-side-effect/ |
my account
